X

Trial Profile

APG101 in Transfusion-Dependent Patients With Low or Intermediate Risk Myelodysplastic Syndrome

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asunercept (Primary)
Indications Myelodysplastic syndromes
Focus Adverse reactions
Sponsors Apogenix

Most Recent Events

28 Mar 2024 Results assessing the effect of Asunercept therapy on the clonal bone marrow composition to identify potential biomarkers to predict response published in the Annals of Hematology
06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
05 Dec 2016 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com